Effects of terazosin on serum lipid levels in hypertensive blacks.
The effects of terazosin, a new, selective, alpha 1-adrenoceptor antagonist, on the serum lipid levels were examined in 103 black patients with uncomplicated, mild to moderate essential hypertension in six randomized, double-blind, placebo-controlled trials conducted in the United States. Terazosin produced statistically significant (P less than 0.05) reductions in total serum cholesterol and triglyceride levels and a marginally significant (P = 0.080) reduction in the combined low-density lipoprotein (LDL-C) and very-low-density lipoprotein (VLDL-C) cholesterol fraction when compared with placebo. We conclude that terazosin, unlike thiazide diuretics, has a favourable effect on the serum lipid profiles of hypertensive blacks.
Luther
R R
RR
Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064-3500.
Klepper
M J
MJ
Maurath
C J
CJ
Glassman
H N
HN
Achari
R
R
Laddu
A R
AR
D000293:Adolescent; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D000328:Adult; D000368:Aged; D044383:Black People; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011224:Prazosin / Q000031:analogs & derivatives* / Q000494:pharmacology
D000317:Adrenergic alpha-Antagonists; D008055:Lipids; C041226:Terazosin; D011224:Prazosin